6950-88-5

Usage

Uses

Used in Pharmaceutical Synthesis:
4-(3-methoxy-4-nitrophenyl)morpholine is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of biologically active compounds. Its unique structural features allow for the creation of new drugs with potential therapeutic applications.
Used in Agrochemical Production:
In the agrochemical industry, 4-(3-methoxy-4-nitrophenyl)morpholine serves as an intermediate, playing a crucial role in the synthesis of various agrochemicals aimed at enhancing crop protection and productivity.
Used in Medicinal Chemistry:
4-(3-methoxy-4-nitrophenyl)morpholine is utilized as a building block in medicinal chemistry for its potential to form complex organic molecules that can be further developed into new pharmaceutical agents with specific therapeutic targets.
Used in Organic Synthesis:
As a versatile chemical compound, 4-(3-methoxy-4-nitrophenyl)morpholine is used in organic synthesis to create a wide range of organic molecules, taking advantage of its reactivity and selectivity to achieve specific synthetic goals.
Used in Material Science:
In the field of material science, 4-(3-methoxy-4-nitrophenyl)morpholine may be employed in the development of new materials with unique properties, leveraging its structural attributes to contribute to advances in material design and functionality.

InChI:InChI=1/C11H14N2O4/c1-16-11-8-9(2-3-10(11)13(14)15)12-4-6-17-7-5-12/h2-3,8H,4-7H2,1H3

Upstream product

• 110-91-8 morpholine 
• 6627-53-8 1-chloro-3-methoxy-4-nitrobenzene 
• 74-88-4 methyl iodide 
• 175135-19-0 AMA₅₆ 
• 448-19-1 4-fluoro-2-methoxy-1-nitrobenzene 

Downstream Products

• 209960-91-8 2-methoxy-4-morpholinoaniline 
• 1372263-46-1 N₄-benzyl-N₂-(2-methoxy-4-morpholinophenyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine 
• 1372262-88-8 N-(2-methoxy-4-morpholinophenyl)-4-(methylthio)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine 
• 1372262-89-9 N-(2-methoxy-4-morpholinophenyl)-4-(methylsulfonyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine 
• 1372262-90-2 N-ethyl-N-(3-((2-(2-methoxy-4-morpholinophenylamino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)methyl)pyridin-2-yl)methanesulfonamide 
• 1372262-84-4 N-ethyl-N-{3-[( {2-[(2-methoxy-4-morpholin-4-ylphenyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}amino)methyl]pyridin-2-yl}methanesulfonamide 
• 1312162-29-0 2-(2-(2-methoxy-4-morpholinophenylamino)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N-methylbenzamide 
• 1312163-37-3 4-chloro-N-(2-methoxy-4-morpholinophenyl)-7-(4-methoxybenzyl)-6,7-dihydro-5H-pyrrolO[2,3-d]pyrimidin-2-amine 
• 1312163-38-4 2-(2-(2-methoxy-4-morpholinophenylamino)-7-(4-methoxybenzyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N-methylbenzamide 
• 1246529-79-2 N₆-cyclohexyl-N₂-[2-methoxy-4-(morpholin-4-yl)phenyl]-9H-purine-2,6-diamine 
• 1395171-68-2 C₂₇H₃₇N₇O₃ 

Relevant academic research and scientific papers

Optimization of WZ4003 as NUAK inhibitors against human colorectal cancer

NUAK, the member of AMPK (AMP-activated protein kinase) family of protein kinases, is phosphorylated and activated by the LKB1 (liver kinase B1) tumor suppressor protein kinase. Recent work has indicated that NUAK1 is a key component of the antioxidant stress response pathway, and the inhibition of NUAK1 will suppress the growth and survival of colorectal tumors. As a promising target for anticancer drugs, few inhibitors of NUAK were developed. With this goal in mind, based on NUAK inhibitor WZ4003, a series of derivatives has been synthesized and evaluated for anticancer activity. Compound 9q, a derivative of WZ4003 by removing a methoxy group, was found to be the most potential one with stronger inhibitory against NUAK1/2 enzyme activity, tumor cell proliferation and inducing apoptosis of tumor cells. By in vivo efficacy evaluations of colorectal SW480 xenografts, 9q suppresses tumor growth more effectively with an excellent safety profile in vivo and is therefore seen as a suitable candidate for further investigation.

Discovery and structure ? activity relationship exploration of pyrazolo[1,5-a]pyrimidine derivatives as potent FLT3-ITD inhibitors

Internal tandem duplications of FLT3 (FLT3-ITD) occur in approximately 25% of all acute myeloid leukemia (AML) cases and confer a poor prognosis. Optimization of the screening hit 1 from our in-house compound library led to the discovery of a series of pyrazolo[1,5-a]pyrimidine derivatives as potent and selective FLT3-ITD inhibitors. Compounds 17 and 19 displayed potent FLT3-ITD activities both with IC50 values of 0.4 nM and excellent antiproliferative activities against AML cell lines. Especially, compounds 17 and 19 inhibited the quizartinib resistance- conferring mutations, FLT3D835Y, both with IC50 values of 0.3 nM. Moreover, western blot analysis indicated that compounds 17 and 19 potently inhibited the phosphorylation of FLT3 and attenuated downstream signaling in AML cells. These results indicated that pyrazolo[1,5-a]pyrimidine derivatives could be promising FLT3-ITD inhibitors for the treatment AML.

Design, synthesis and biological evaluation of novel pteridinone derivatives as potent dual inhibitors of PLK1 and BRD4

To develop novel simultaneous inhibition of PLK1 and BRD4 bromodomain by a single molecule, three series of novel pteridinone derivatives were designed, synthesized and evaluated for their biological activity. Most compounds exhibited moderate to excellent cytotoxic activity against A549, HCT116, PC-3 and MCF-7 cell lines. The most promising compound III4 showed high antiproliferative effects on four cell lines with IC50 values of 1.27 μM, 1.36 μM, 3.85 μM and 4.06 μM, respectively. The enzymatic assay identified III4 as a potent PLK1 and BRD4 dual inhibitor with % inhibition values of 96.6 and 59.1, respectively. Furthermore, to clarify the anticancer mechanism of the target compounds, explorations in the bioactivity were conducted. The results showed that compound III4 obviously inhibited the proliferation of HCT-116 cell lines, induced a great decrease in the mitochondrial membrane potential leading to apoptosis of cancer cells, suppressed the migration of tumor cells, and arrested the S phase of HCT116 cells.

A class of FLT3 kinase inhibitors, preparation and application thereof

The invention relates to a class of FLT3 kinase inhibitors, preparation and application thereof, wherein specifically the compound has a structure represented by a formula (I), and all groups and substituents are defined in the specification. The invention also discloses a preparation method of the compound, and application of the compound in inhibition of FLT3.

Aminopyrimidine compound and application thereof in anti-cancer drugs

The invention provides an aminopyrimidine compound and application thereof in anti-cancer drugs. The compound is of the structure shown in the general formula (I), wherein m is 0-4, and n is 0-4; R1 is selected from amino, an alkyl amino group, an amino alkyl group and an alkyl amino carbonyl group; R2 is selected from hydrogen, hydroxyl, nitro, halogen, amino, a cyano group, an alkyl group, an alkenyl group, a halogen alkyl group, a hetero alkyl group, an alkyl amino group, an amino alkyl group, an alkyl carbonyl group, an alkyl amino carbonyl group and a aryl carbonyl group; X is selected from an oxygen atom, an amino group or a methylamino group. The compound can be used for improving the inhibition rate of EGFRT790M and has higher anticancer activity.

Imidazopyridazine IRAK4 inhibitor, and preparation method and application thereof

The invention belongs to the field of medicines, and especially relates to an imidazopyridazine compound or a pharmaceutically acceptable salt thereof, a preparation method thereof, and an applicationof a medicinal composition of the compound or the salt in the treatment of tumors, inflammations, immunity and other diseases. The imidazopyridazine compound is a novel protein kinase IRAK4 inhibitor, and can selectively inhibit IRAK4 and downstream signaling pathways thereof. The compound has the structural formula I.

NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS FAK/AURORA KINASE INHIBITORS

This invention relates to certain novel pyrimidine derivatives of the Formula (I). The invention also relates to process for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer.

PYRIMIDINE DERIVATIVE AND USE THEREOF

The present invention provides a pyrimidine derivative and a use thereof. The pyrimidine derivative is the compound shown in formula I or a pharmaceutically acceptable salt, hydrate, solvate, metabolite or prodrug thereof, wherein, R1, R2, R3, R4 and R5 are, for example, as defined in the specification. The compound can act as an ALK inhibitor, and is for preparing an anti-tumor medicament for suppressing an anaplastic lymphoma kinase.

2,4-dibasic miazines compound

The invention belongs to the field of medical chemistry, relates to a 2,4-dibasic miazines compound and specifically relates to a compound shown as formula (I) or a pharmaceutically acceptable salt thereof, a drug compound thereof and an application thereof in treating EGFR or/and ALK mediated diseases.

Heterocyclic derivate tyrosine kinase inhibitor

The invention belongs to the technical field of medicine and particularly relates to a heterocyclic derivate tyrosine kinase inhibitor shown in the formula (I), a pharmaceutically acceptable salt and ester thereof and stereoisomers thereof, wherein Y, W, Q m, L, R1, R2, R3, R4, R5, R6, R7, R7', R8 and R8' are defined in the specification. The invention further relates to a preparation method of the compounds and a pharmaceutical preparation and pharmaceutical compositions containing the compounds, and application of the compounds as the tyrosine kinase inhibitor for preparing medicine for preventing and/or treating cancer diseases caused by EGFR mutation and drug resistance diseases caused by EGFR T790M mutation.